Fig. 5: Administration of TARM1-Fc attenuates the development of CIA.

a Severity score of arthritic joints from CIA-induced DBA/1J mice treated with TARM1-Fc or IgG Fc. TARM1-Fc and IgG Fc (1 μg/30 μl for each) were administrated into the articular cavity of the left and right knee joints of a CIA-induced mouse, respectively, and the severity scores of IgG Fc- (black) or TARM1-Fc-injected paw (red) were measured separately. Data from two independent experiments are combined (n = 12). Mean ± SD. *P < 0.05; **P < 0.01 (two-tailed Mann–Whitney U test). b Representative photograph of feet treated with TARM1-Fc (left) or IgG Fc (right) as shown in a. c, d Histology of the HE-stained ankle joint at day 14 after TARM1-Fc or IgG Fc treatment (c). Data are representative of six mice. Histological score of synovitis, pannus formation, and bone erosion of ankle joints are shown in (d). Mean ± SD. Scale bar, 100 μm. *P < 0.05 (two-tailed Mann–Whitney U test). e Gene expressions in arthritic ankles and tarsal joints from TARM1-Fc- or IgG Fc-treated legs were analyzed by qPCR (n = 6). Mean ± SD. *P < 0.05 (two-tailed unpaired t test). Source data are provided as a Source data file.